New Drug Shows Promise Against Seizures in Clinical Trial

Researchers at University College London are leading an international clinical trial for the drug zorevunersen, an antisense oligonucleotide that treats a rare form of genetic childhood epilepsy called Dravet syndrome. The disease results in an underperforming SCN1A gene, which the drug can boost.

Not only did researchers report up to a 91% decrease in seizures for trial participants, but they also reported other beneficial results in cognitive function and behavior, which are also typically affected by the disease.

81 children participated in the study, and no notable harmful side effects were reported.

For more, head over to ScienceDaily.